Acral Lentiginous Melanoma Cell Line - (HBL (MM001))

Sabbah,   M.; Krayem, M.; Najem, A.; Sales, F.; Miller, W.; Del Rincon, S.; Awada, A.;  Ghanem, G.E.; Journe, F. Dasatinib Stimulates Its Own Mechanism of Resistance   by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified   c-Kit. Mol Cancer Res 2021, 19, 1221?1233, doi:10.1158/1541-7786.MCR-20-1040    Krayem, M.; Journe, F.; Wiedig, M.; Morandini, R.; Sales, F.;   Awada, A.; Ghanem, G. Prominent Role of Cyclic Adenosine Monophosphate   Signalling Pathway in the Sensitivity of (WT)BRAF/(WT)NRAS Melanoma Cells to   Vemurafenib. Eur. J. Cancer 2014, 50, 1310?1320, doi:10.1016/j.ejca.2014.01.021.    Krayem, M.; Najem, A.; Journe, F.; Morandini, R.; Sales, F.;   Awada, A.; Ghanem, G.E. Acquired Resistance to BRAFi Reverses Senescence-like   Phenotype in Mutant BRAF Melanoma. Oncotarget 2018, 9, 31888?31903,  doi:10.18632/oncotarget.25879.    Soumoy, L.; Schepkens, C.; Krayem, M.; Najem, A.; Tagliatti, V.;   Ghanem, G.E.; Saussez, S.; Colet, J.-M.; Journe, F. Metabolic Reprogramming   in Metastatic Melanoma with Acquired Resistance to Targeted Therapies:   Integrative Metabolomic and Proteomic Analysis. Cancers   (Basel) 2020, 12,   E1323, doi:10.3390/cancers12051323.    Wouters, J.; Kalender-Atak, Z.; Minnoye, L.; Spanier, K.I.; De   Waegeneer, M.; Bravo González-Blas, C.; Mauduit, D.; Davie, K.; Hulselmans,   G.; Najem, A.; et al. Robust Gene Expression Programs Underlie Recurrent Cell   States and Phenotype Switching in Melanoma. Nat Cell Biol 2020, 22, 986?998,   doi:10.1038/s41556-020-0547-3.    Verfaillie, A.; Imrichova, H.; Atak, Z.K.; Dewaele, M.; Rambow,   F.; Hulselmans, G.; Christiaens, V.; Svetlichnyy, D.; Luciani, F.; Van den   Mooter, L.; et al. Decoding the Regulatory Landscape of Melanoma Reveals   TEADS as Regulators of the Invasive Cell State. Nature   Communications 2015, 6,   6683, doi:10.1038/ncomms7683.    Gembarska, A.; Luciani, F.; Fedele, C.; Russell, E.A.; Dewaele,   M.; Villar, S.; Zwolinska, A.; Haupt, S.; de Lange, J.; Yip, D.; et al. MDM4   Is a Key Therapeutic Target in Cutaneous Melanoma. Nat   Med 2012, 18,   10.1038/nm.2863, doi:10.1038/nm.2863.    Aftimos, P.G.; Wiedig, M.; Langouo Fontsa, M.; Awada, A.;   Ghanem, G.; Journe, F. Sequential Use of Protein Kinase Inhibitors   Potentiates Their Toxicity to Melanoma Cells: A Rationale to Combine Targeted   Drugs Based on Protein Expression Inhibition Profiles. Int.   J. Oncol. 2013, 43,   919?926, doi:10.3892/ijo.2013.2008    Eves, P.; Haycock, J.; Layton, C.; Wagner, M.; Kemp, H.; Szabo,   M.; Morandini, R.; Ghanem, G.; García-Borrón, J.C.; Jim?nez-Cervantes, C.; et   al. Anti-Inflammatory and Anti-Invasive Effects of   Alpha-Melanocyte-Stimulating Hormone in Human Melanoma Cells. Br J Cancer 2003, 89, 2004?2015, doi:10.1038/sj.bjc.6601349.    Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L.,   Maida I., Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S.,   Tommasi S., Guida M., Azzariti A.Aurora kinase B inhibition reduces the proliferation of metastatic melanoma   cells and enhances the response to chemotherapy. J. Transl. Med. 13:26.1-26.13(2015) doiI=10.1186/s12967-015-0385-4    Zanna P., Maida I., Grieco C., Guida S., Turpin Sevilla M.C., De   Summa S., Tommasi S., Vena G.A., Filotico R., Guida G. Three novel human   sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and   beta-catenins. J. Biol. Regul. Homeost. Agents 27:131-14 PubMed=23489693    Mauduit, D.; Taskiran, I.I.; Minnoye, L.; Waegeneer, M. de;   Christiaens, V.; Hulselmans, G.; Demeulemeester, J.; Wouters, J.; Aerts, S.   Analysis of Long and Short Enhancers in Melanoma Cell States. eLife 2021, 10,   doi:10.7554/eLife.71735.    Huang, F.; Gon?alves, C.; Bartish, M.; R?my-Sarrazin, J.; Issa,   M.E.; Cordeiro, B.; Guo, Q.; Emond, A.; Attias, M.; Yang, W.; et al.   Inhibiting the MNK1/2-EIF4E Axis Impairs Melanoma Phenotype Switching and   Potentiates Antitumor Immune Responses. J Clin Invest 2021, 131,   doi:10.1172/JCI140752.